Home › Upcoming votes › ABVC BIOPHARMA, INC.
This meeting took place on October 28, 2026. Official results not yet filed. Companies report them on Form 8-K, usually within four business days of the meeting; they will appear here once they have been read.
The deadline as the proxy statement states it: “vote in favor of each of the proposals by so indicating on the enclosed Proxy and by signing and returning the enclosed Proxy as promptly as possible, before 11:59 p.m. Eastern Time on October 27, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot: see the proxy statement. The items on this ballot could not be read from the filing with enough confidence to list them here. Read the proxy statement.
From ABVC BIOPHARMA, INC.’s Form 8-K, filed June 4, 2025, for the meeting held June 3, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Eugene Jiang | 99.6% | Elected |
| Elect Director: Dr. Tsang Ming Jiang | 99.6% | Elected |
| Elect Director: Norimi Sakamoto | 99.6% | Elected |
| Elect Director: Yen-Hsin Chou | 99.6% | Elected |
| Elect Director: Dr. Tsung-Shann (T.S.) Jiang | 99.6% | Elected |
| Elect Director: Dr. Chang-Jen Jiang | 99.6% | Elected |
| Elect Director: Hsin-Hui Miao | 99.6% | Elected |
| Elect Director: Yoshinobu Odaira | 99.6% | Elected |
| Elect Director: Che-Wei Hsu | 99.6% | Elected |
| Elect Director: Shuling Jiang | 99.6% | Elected |
| Elect Director: Yu-Min (Francis) Chung | 99.6% | Elected |
| 2. To ratify the appointment of Simon & Edward, LLP as the Company's independent registered public accounting firm for fiscal year ending De | 99.8% | — |
| 3. To authorize, for purposes of complying with Nasdaq Listing Rule 5635(b) and Nasdaq Listing Rule 5635(d), the entry into an agreement to | 99% | Approved |
| 4. To approve an increase in the Company's Amended and Restated 2016 Equity Incentive Plan (the " Plan ") up to a maximum of 15% of the numb | 96% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.